Lesson
Move From Skin Delivery to Gene Regulation
A topical corticosteroid must reach viable skin, cross cell membranes, bind the glucocorticoid receptor, and change inflammatory transcription. The same mechanism that controls disease can suppress repair and host defense.
- Glucocorticoid receptor
- Transcription
- Cytokines
- Eicosanoids
- Vasoconstriction
Vehicle and barrier determine delivery
The complex changes location and activity
Cytokines and eicosanoid signaling decline
Diagnosis still determines whether suppression is appropriate
Reach the target tissue
Percutaneous delivery begins at the stratum corneum. Vehicle, hydration, barrier integrity, inflammation, body site, area, and occlusion determine how much drug reaches living tissue.
Activate the receptor
Lipophilic corticosteroid enters the cell and binds a cytosolic glucocorticoid receptor. The activated complex changes nuclear transcription and interacts with inflammatory signaling networks.
Reduce inflammatory output
Glucocorticoid signaling induces anti-inflammatory proteins and reduces phospholipase, eicosanoid, cytokine, immune-cell, and vascular activity.
Respect mechanism limits
Suppression is not diagnosis. Tinea, bacterial infection, herpes, acne, rosacea, and perioral dermatitis can temporarily look quieter while the underlying process persists or worsens.
Quick check
Checking for saved practice…
Lesson
Treat Potency as a Product Property
Topical corticosteroids span low through super-high potency. Molecule, salt or ester, concentration, vehicle, assay, and exact formulation determine class, so ingredient names cannot be ranked in isolation.
- Seven groups
- Concentration
- Vehicle
- Hydrocortisone
- Clobetasol
Useful where safety margin is narrow
Match disease, site, and duration
Risk rises with area and exposure
Strict label limits and monitoring apply
Interpret differences between potency tables
The AAAAI/ACAAI table places fluocinolone 0.025% ointment in group 4 and its cream in group 5; fluticasone 0.05% cream is group 4 and lotion group 5. These distinctions clarify broad or repeated entries in the book. Potency is a continuum: some labels use a wider medium range, and classifications may differ slightly. Identify the source and formulation instead of treating adjacent groups as a contradiction or an automatic substitution rule.
Read beyond the ingredient
Different concentrations and vehicles of one corticosteroid can occupy different potency groups. Confirm the active ingredient, concentration, dosage form, and label rather than relying on memory.
Read triamcinolone acetonide as molecular design
Triamcinolone acetonide is an active corticosteroid with a fluorine substitution and a cyclic 16,17 acetal formed with acetone. It binds the glucocorticoid receptor; it does not need to be described as an inactive triamcinolone precursor. A structural study using an ancestral receptor model showed hydrophobic contacts involving the acetonide group. That laboratory finding helps explain ligand recognition, but does not determine a cream's potency class, skin residence time or clinical duration. Use product evidence for those decisions.
Use low potency deliberately
OTC hydrocortisone 0.5 to 1 percent provides temporary relief for selected mild inflammatory rashes. Thin skin and self-care do not remove the need for site and duration limits.
Reserve high potency for a reason
Thick plaques and resistant sites may require higher potency, but large area, prolonged use, occlusion, children, fragile skin, and impaired barrier increase toxicity.
Anchor super-high potency to the label
The reviewed clobetasol propionate 0.05% emollient cream uses a thin layer twice daily. For responsive dermatoses in patients at least 12 years old, treatment is limited to two weeks and 50 g/week. A specific exception allows up to four weeks for moderate-to-severe plaque psoriasis affecting 5-10% body surface area in patients at least 16 years old, still within 50 g/week. Stop when controlled; reassess if not improving within two weeks. These are product-specific limits.
Quick check
Checking for saved practice…
Lesson
Resolve the Product Before the Potency Number
A concentration or generic name alone cannot settle a substitution. Compare the complete formulation and its labeled use.
- Augmented vehicle
- Measured potency
- Disease-specific frequency
- Age
- Quantity ceiling
Check the complete product
Do not infer equivalence
Schedules can differ by disease
Resolve every mismatch
OTC hydrocortisone still needs a product check
The reviewed 0.5% cream and 1% ointment allow skin-itch self-care from age 2, no more than three to four applications daily; younger children need medical advice. The reviewed 1% lotion carries eczema-related itch directions at the same age and frequency, with other uses requiring clinician advice. Do not treat diaper rash without medical advice. Stop and seek advice if symptoms worsen, last beyond seven days or quickly recur; switching hydrocortisone products does not restart the self-care window. Check site-specific restrictions, including external anal use, on the actual package.
Hydrocortisone lotion needs its own directions
The reviewed prescription hydrocortisone 2.5% lotion contains 25 mg/mL. Shake before applying a thin film two to four times daily as prescribed. Do not import an OTC cream self-care plan or a hydrocortisone butyrate schedule. Covering requires clinician direction; stop occlusion and treat appropriately if infection develops. Review vehicle ingredients when contact allergy is suspected.
Betamethasone: augmentation and dosage form matter
The reviewed augmented betamethasone dipropionate 0.05% cream is high potency; the reviewed augmented ointment is super-high potency. Their labels permit once- or twice-daily use from age 13 and limit use to 50 g/week. Matching ingredient and percentage does not make these dosage forms interchangeable.
Fluocinonide: one product, different disease schedules
The reviewed fluocinonide 0.1% cream is super-high potency, for patients at least 12 years old. Atopic dermatitis uses once-daily treatment; psoriasis permits once or twice daily, with better two-week treatment success for twice-daily use in the label's psoriasis trial. Limit use to two weeks and 60 g/week; stop when controlled and reassess nonresponse. Avoid face, groin, axillae, rosacea and perioral dermatitis.
Fluocinonide 0.05% is a separate prescribing check
The reviewed 0.05% cream, emulsified cream, gel, ointment and solution labels specify a thin film two to four times daily according to severity. Do not automatically copy the 0.1% cream schedule or age indication. The solution label reports greater absorption than cream or gel, illustrating why identical percentages do not establish identical exposure. Its alcohol-containing vehicle can severely irritate the eyes; flush accidental eye exposure promptly with plenty of water and obtain assessment for persistent symptoms.
Nonaugmented betamethasone has formulation-specific directions
The reviewed nonaugmented betamethasone dipropionate 0.05% cream and ointment label specifies once daily, with twice daily sometimes needed. The lotion uses a few drops twice daily, gently massaged in; shake before use. These products should not be used with occlusive dressings. Confirm the complete prescription rather than importing an augmented product's instructions.
Augmented lotion has a volume limit
The reviewed augmented betamethasone dipropionate 0.05% lotion is super-high potency, for patients at least 13 years old. Apply a few drops once or twice daily; stop when controlled. Limit treatment to two consecutive weeks and no more than 50 mL/week. Reassess nonresponse at two weeks. Avoid face, groin, axillae, diaper dermatitis and sites with skin atrophy; occlusion requires clinician direction. A lotion limit in milliliters must not be copied as grams.
Valerate is a different betamethasone ester
The reviewed betamethasone valerate 0.1% cream and ointment instructions permit one to three applications daily, noting that once or twice daily is often effective. The lotion starts twice daily and reduces to once daily after improvement under the treatment plan. Do not confuse these products with dipropionate preparations or transfer the 0.12% foam instructions. Occlusion requires clinician direction.
Ordinary clobetasol semisolids keep the two-week limit
The reviewed clobetasol 0.05% gel, ordinary cream and ointment are super-high potency, applied twice daily for no more than two consecutive weeks and 50 g/week. Stop when controlled and reassess nonresponse at two weeks. Their label does not recommend use below age 12 and states pediatric safety and effectiveness are not established. Avoid face, groin, axillae, rosacea, perioral dermatitis and occlusive dressings. The emollient cream's selected psoriasis extension does not transfer to these preparations.
Halobetasol cream has its own frequency
The reviewed halobetasol propionate 0.05% cream is super-high potency and uses once- or twice-daily application, limited to two weeks and 50 g/week. Stop when controlled; reassess nonresponse at two weeks. Pediatric safety and effectiveness are not established, and use below age 12 is not recommended. Avoid face, groin, axillae, rosacea, perioral dermatitis and occlusive dressings. Do not transfer the lotion's twice-daily schedule automatically.
Mometasone: identify the classification system
The reviewed mometasone furoate 0.1% ointment label calls it medium potency; some seven-group references place it toward the stronger end of the middle range. Use once daily from age 2, stop when controlled, and reassess no improvement at two weeks. Pediatric safety beyond three weeks is not established. Avoid face, groin, axillae and diaper use; no occlusion unless directed.
Mometasone cream has its own instructions
The reviewed mometasone furoate 0.1% cream is medium potency, used once daily from age 2. Stop when controlled; reassess nonresponse at two weeks. Pediatric use beyond three weeks is not established. Avoid face, groin, axillae and diaper-area use; occlusion requires clinician direction. Similar schedules do not establish cream-ointment interchangeability.
Hydrocortisone butyrate solution has a narrower indication
The reviewed ordinary 0.1% cream and ointment labels cover corticosteroid-responsive dermatoses; the 0.1% solution label specifies seborrheic dermatitis. All three specify a thin film two or three times daily according to severity. The solution contains 50% v/v isopropyl alcohol. Do not transfer the lipid cream or lotion infant indication to these preparations. Occlusion requires clinician direction.
Triamcinolone cream requires a complete regimen
The reviewed triamcinolone acetonide 0.1% cream label specifies two or three daily applications for corticosteroid-responsive dermatoses. Its occlusion technique is a clinician-directed option for resistant disease, with added attention to infection, adrenal effects and impaired heat regulation. Stop occlusive covering if infection develops and obtain appropriate treatment. Neither the aerosol schedule nor a different cream strength substitutes for this product-specific plan.
Prescription hydrocortisone is not an OTC substitution rule
The reviewed hydrocortisone 2.5% cream and ointment contain 25 mg/g and specify a thin film two to four times daily according to severity. Use the prescribed diagnosis, site and follow-up plan; the higher percentage does not make hydrocortisone equivalent to hydrocortisone butyrate. Do not add occlusive covering without clinician direction, and use particular care with children.
Fluticasone: do not transfer pediatric eligibility
The reviewed fluticasone propionate 0.005% ointment is labeled medium potency for adults, twice daily. Pediatric use is not recommended. Avoid occlusive dressings; face, groin and underarm treatment require clinician direction. Seek review for worsening symptoms or no improvement after two weeks. A different fluticasone dosage form or concentration has its own labeling; the shared drug name does not carry over an age indication.
Fluticasone cream and lotion differ from the ointment
The reviewed fluticasone 0.05% cream permits use from age 3 months: once or twice daily for atopic dermatitis, twice daily for other corticosteroid-responsive dermatoses. Pediatric use beyond four weeks is not established. The reviewed 0.05% lotion is indicated for atopic dermatitis from age 3 months, once daily; use beyond four weeks is not established. Both require stopping when controlled and reassessment of no improvement at two weeks. Avoid occlusion and diaper-area use.
Excipients can explain a failure to heal
The reviewed fluticasone cream and lotion contain imidurea, which can release formaldehyde. Avoid these formulations in formaldehyde hypersensitivity; irritation or failure to heal warrants review of the drug and vehicle rather than automatic escalation of steroid strength.
Recognize historical hydrocortisone probutate
The book includes hydrocortisone probutate 0.1% cream (Pandel). The FDA product record checked in September 2026 lists it as discontinued. Its historical US label restricted use to adults at least 18 years old, once or twice daily, stopping when controlled and reassessing nonresponse at two weeks. Retain the example for formulation literacy; do not present it as a currently marketed alternative or confuse probutate with hydrocortisone butyrate.
Distinguish prednicarbate cream from ointment
Prednicarbate 0.1% emollient cream is a medium-potency historical example. The FDA records checked in September 2026 list the brand and generic creams as discontinued, while one generic ointment record remains prescription status. This does not establish pharmacy stock or authorize substitution. The historical cream label permitted cautious use from age 1, twice daily; pediatric use beyond three weeks was not established. Discontinued status alone does not mean withdrawal for harm: the brand cream record explicitly notes a determination that discontinuation was not for safety or effectiveness reasons.
Separate an assay from a clinical outcome
Vasoconstrictor testing helps classify strength. Similar blanching scores do not prove equal efficacy, equal safety, or therapeutic interchangeability. A higher numeric concentration also does not establish a proportional increase in clinical effect.
Quick check
Checking for saved practice…
Lesson
Check the Boundaries of More Potent Formulations
Products near the stronger end of the potency range still differ in indication, schedule, site exclusions and formulation. These examples require their own instructions.
- Halobetasol
- Diflorasone
- Desoximetasone
- Halcinonide
- Label comparison
Spreadability is not authorization
Potency alone does not set frequency
An assay does not establish systemic safety
A missing numeric ceiling is not unlimited use
Augmented betamethasone gel has its own limits
The reviewed augmented betamethasone dipropionate 0.05% gel is super-high potency: a thin layer once or twice daily, no longer than two consecutive weeks and no more than 50 g/week. Pediatric data are unavailable and use under age 12 is not recommended; this is not the same age statement as the augmented cream. Avoid face, groin, axillae, rosacea, perioral dermatitis and occlusive dressings. A labeled maximum is not a guarantee against adrenal suppression.
Clobetasol lotion has a conditional extension
The reviewed clobetasol 0.05% lotion is for adults at least 18, twice daily, limited to two weeks and 50 g (50 mL)/week. A clinician may extend to four weeks only for insufficiently improved localized moderate to severe plaque psoriasis involving less than 10% body surface area, after weighing adrenal-suppression risk. Stop when controlled and reassess nonresponse at two weeks. Avoid face, groin, axillae, skin atrophy, rosacea and perioral dermatitis; covering requires clinician direction.
Clobetasol spray has separate application and weekly limits
The reviewed clobetasol 0.05% spray treats moderate to severe plaque psoriasis involving up to 20% body surface area in adults at least 18. Spray twice daily and rub in; limits are 26 sprays/application, 52/day and 50 g (59 mL)/week. Stop when controlled; reassess at two weeks. Extension to four weeks requires clinician benefit-risk review for persistent localized lesions. Avoid face, groin, axillae, atrophic skin, rosacea and perioral dermatitis. Covering requires clinician direction. Avoid heat, flame and smoking. The pharmacist installs the supplied pump; the patient relocks its nozzle after use.
Halobetasol lotion is not a generic scalp solution
The reviewed halobetasol propionate 0.05% lotion is super-high potency and labeled for plaque psoriasis from age 12. Apply twice daily for no more than two weeks, within 50 g/week; stop when controlled and reassess nonresponse. Avoid the face, scalp, groin and axillae. A spreadable lotion is not automatically suitable for hair-bearing scalp disease.
Halobetasol ointment retains its own pediatric caveat
The reviewed halobetasol 0.05% ointment is super-high potency for corticosteroid-responsive dermatoses, once or twice daily. Limit treatment to two consecutive weeks and 50 g/week; stop when controlled and reassess nonresponse. Its label states pediatric safety and effectiveness are not established and discourages use below age 12. Avoid face, groin, axillae, rosacea, perioral dermatitis and occlusive dressings. The foam age indication does not transfer.
Halobetasol foam has psoriasis-specific eligibility
The reviewed halobetasol 0.05% foam is super-high potency for plaque psoriasis from age 12, twice daily for at most two weeks and no more than 50 g/week. Stop when controlled and reassess nonresponse. Shake well, invert completely and dispense a small amount into the palm, then spread a thin layer. Avoid face, groin, axillae and eyes; occlusion requires clinician direction. Avoid heat, flame and smoking during and immediately after use. An adolescent indication does not remove adrenal-suppression risk.
Diflorasone cream and ointment have different directions
For the reviewed diflorasone diacetate 0.05% products, cream is labeled high potency and twice daily, while the ointment directions allow one to three applications daily according to the condition. Do not transfer a once-daily class shortcut to either prescription. The AAAAI/ACAAI table places the ointment in group 2, high potency, rather than the book's very-high group. Source classifications vary; neither ranking alone establishes systemic safety.
Do not equate potency ranking with endocrine safety
The diflorasone cream label describes greater adrenal suppression than the ointment in small exposure studies. This does not establish a universal cream-versus-ointment rule or a safe dose for unsupervised use. Potency assays and systemic exposure answer different questions.
Desoximetasone requires both strength and vehicle
The book's distinctions are consistent with the seven-group guideline: 0.25% cream and 0.05% gel are high-potency examples; 0.05% cream is in the medium-high group. The reviewed combined product label directs twice-daily use for all three and stopping when controlled. Its four-week nonresponse contact instruction is not a universal four-week treatment authorization.
Halcinonide is another frequency exception
Halcinonide 0.1% cream is a high-potency example in the guideline. Its reviewed label specifies two to three applications daily. Occlusion is clinician-directed; its label also discusses impaired heat regulation with occlusive treatment. Review fever, infection and excessive exposure rather than simply continuing a wrap.
Set an individualized review point
An older label without a numeric weekly ceiling does not mean unlimited dosing is safe. Document area, quantity, duration, response and adverse effects, and reconcile the prescription with the diagnosis and current disease guidance.
Quick check
Checking for saved practice…
Lesson
Match Pediatric Use to the Exact Preparation
Age limits, indications and schedules can change when the same corticosteroid is supplied in a different vehicle.
- Pediatric indication
- Desonide
- Alclometasone
- Hydrocortisone butyrate
- Off-label use
Approval belongs to the preparation
Age alone is insufficient
A diaper can act as occlusion
Use the product-specific follow-up plan
Desonide gel has its own pediatric indication
The reviewed desonide 0.05% gel is labeled for mild to moderate atopic dermatitis from age 3 months, twice daily. Stop once controlled; do not exceed four consecutive weeks. Avoid occlusive dressings and diaper-area application. Its age indication does not establish that every desonide preparation has the same pediatric evidence.
Recognize the historical desonide foam formulation
FDA records checked in September 2026 list Verdeso 0.05% foam as discontinued. Its last linked label covers mild to moderate atopic dermatitis from age 3 months, twice daily, stopping when controlled and not exceeding four consecutive weeks. Shake and invert the can. For facial treatment, dispense into the hand first; avoid eyes. Keep away from flame and smoking during and immediately after application. Occlusion requires clinician direction. These historical instructions do not establish current availability or transfer to other desonide vehicles.
Desonide cream and lotion require a separate check
The reviewed 0.05% cream/lotion label states that pediatric safety and effectiveness have not been established. Its directions specify two or three applications daily, stopping when controlled and reassessing no improvement at two weeks; shake the lotion. A clinician may make an individualized off-label decision, but a gel indication cannot be presented as approval for these products.
Alclometasone is not an unrestricted infant steroid
The reviewed alclometasone dipropionate 0.05% cream and ointment labels permit use from age 1 year, with two or three daily applications. Pediatric use beyond three weeks has not been established. Stop when controlled and reassess nonresponse at two weeks. Avoid diaper use; face, folds and occlusion require specific clinician directions.
Hydrocortisone butyrate is a distinct prescription product
The reviewed hydrocortisone butyrate 0.1% lipid cream has a pediatric mild-to-moderate atopic dermatitis indication from age 3 months, twice daily. Adult corticosteroid-responsive dermatoses use two or three applications daily. Do not substitute OTC hydrocortisone directions. Stop when controlled; reassess at two weeks, and weigh benefit against adrenal and local risks before extending toward four weeks. Avoid the diaper area; face, folds and occlusion require clinician direction.
Hydrocortisone butyrate lotion uses a two-week review point
The reviewed 0.1% lotion treats mild to moderate atopic dermatitis from age 3 months, twice daily for up to two weeks. Stop when controlled. Nonresponse needs reassessment; extending toward four weeks requires weighing benefit against adrenal and local adverse effects. Avoid diaper-area use; face, folds and covering require clinician direction. The three-times-daily regimen in its adrenal-suppression study is not the approved dosing schedule.
Fluocinolone body oil has age-specific directions
The reviewed fluocinolone acetonide 0.01% body oil treats adult atopic dermatitis three times daily. Its pediatric indication is moderate to severe atopic dermatitis from age 3 months: moisten the skin and apply twice daily for up to four weeks. Stop when controlled and contact the clinician if not improving at two weeks. Avoid diaper-area use and intertriginous application; face, axillae and groin require clinician direction.
Check peanut sensitivity before choosing the oil
This body-oil formulation contains refined peanut oil. Its label calls for prescribing caution in peanut-sensitive patients, not a blanket claim that refined oil is risk-free. Stop the product and obtain appropriate assessment if hypersensitivity or worsening disease occurs. Do not transfer body-oil instructions to scalp or ear products that share the drug name.
An age indication is only one part of the plan
Document diagnosis, exact preparation, treated area, amount, site and reassessment date. A product studied in young children is not permission for unlimited area, prolonged treatment or unsupervised covering. Conversely, a label stating that pediatric evidence is not established does not by itself prove harm or prohibit a carefully justified clinician-directed off-label use.
Quick check
Checking for saved practice…
Lesson
Choose the Vehicle as Part of the Dose
Ointments, creams, lotions, solutions, gels, foams, oils, sprays, shampoos, and tapes change hydration, spread, evaporation, occlusion, tolerability, and adherence.
- Ointment
- Cream
- Solution
- Foam
- Occlusion
Often useful for dry thick lesions
Preservatives can matter
Alcohol can sting disrupted skin
Flammability and product directions matter
Use ointment for occlusive delivery
Ointments have little water, reduce transepidermal water loss, and often suit dry thick nonhairy lesions. Greasiness and follicular occlusion can reduce acceptance.
Use cream for flexible spread
Creams are less greasy and often easier to use in folds or during the day, but preservatives, emulsifiers, and other inactive ingredients can irritate or sensitize.
Reach hair-bearing skin
Solutions, foams, gels, oils, sprays, and shampoos can improve scalp and hair-bearing delivery. Alcohol can sting disrupted skin, and aerosol or foam products may be flammable.
Handle scalp foam correctly
The reviewed betamethasone valerate 0.12% foam is labeled medium potency for responsive scalp dermatoses, twice daily. Its label does not establish pediatric safety and effectiveness. Invert the can and dispense onto a cool surface rather than a warm palm, then part the hair and apply to affected skin. Avoid fire, flame and smoking during and immediately after use; reassess lack of improvement at two weeks.
Emulsion foam uses different dispensing instructions
The reviewed clobetasol 0.05% emulsion foam is labeled for corticosteroid-responsive dermatoses from age 12, twice daily for at most two weeks, with a 50 g or 21-capful weekly ceiling. Stop when controlled and reassess nonresponse at two weeks. Shake, invert and dispense a small amount into the palm before spreading a thin layer. This differs from the ordinary hydroethanolic foam handling in the scalp lesson. Avoid face, folds, atrophic skin, eyes and ignition sources; covering requires clinician direction.
Read aerosol units before comparing concentrations
The reviewed triamcinolone acetonide topical aerosol contains 0.147 mg/g, equivalent to 0.0147% by weight before spraying. Its label describes approximately 0.2% drug in the nonvolatile film after spraying. These refer to different material states; neither number alone ranks clinical potency or gives systemic absorption. The label generally uses three or four daily applications, advises avoiding inhalation and eye exposure, and warns against heat, flame and smoking. Reassess no improvement at two weeks.
Separate fluocinolone semisolids from oil instructions
The reviewed fluocinolone 0.01% and 0.025% creams and 0.025% ointment labels describe two to four applications daily according to severity. They do not establish a blanket infant indication by analogy with body oil. Part hair when needed to reach the lesion; clinician-directed occlusion requires added attention to infection and exposure. A concentration and vehicle change requires a new prescription check.
Deliver fluocinolone solution to the skin
The reviewed fluocinolone acetonide 0.01% topical solution contains 0.1 mg/mL in a water-washable vehicle. Its label specifies a thin film two to four times daily according to severity. Part hair so the solution contacts the lesion. Do not transfer scalp-oil cap and wash-out instructions or body-oil infant eligibility to this solution. Covering requires clinician direction; infection during occlusion requires stopping the covering and appropriate assessment and treatment.
Distinguish flurandrenolide cream and ointment
The reviewed 0.05% cream label describes gentle application to moist lesions; the 0.05% ointment label describes a thin film on dry, scaly lesions. Both use two or three daily applications, stopping when controlled and reassessing nonresponse at two weeks. Both contain 0.5 mg/g. Face, groin, underarms and occlusive dressings require clinician direction. Neither uses the tape schedule or its area-based dose units.
Shake flurandrenolide lotion
The reviewed flurandrenolide 0.05% lotion contains 0.5 mg/mL. Shake before use and gently apply a small amount two or three times daily. Stop when controlled; reassess nonresponse at two weeks. Keep tightly closed, protect from light and avoid freezing. Its liquid directions and concentration are distinct from the medicated tape's micrograms per square centimeter.
Do not rank every vehicle by one ladder
An ointment often increases hydration and penetration, but vehicle names alone cannot rank every product. Concentration, formulation engineering, drug release, and the active molecule also matter. Confirm measured product potency instead of assuming every ointment is stronger than every cream, solution, gel, or spray.
Treat occlusion as a dose multiplier
Wraps, diapers, skin folds, and tape increase hydration and absorption. Occlusive therapy is clinician-directed because local and systemic exposure can rise sharply.
Quick check
Checking for saved practice…
Lesson
Distinguish Scalp Oil From Medicated Shampoo
A shared corticosteroid name does not establish the same diagnosis, age eligibility, preparation or contact time.
- Scalp psoriasis
- Seborrheic dermatitis
- Contact time
- Preparation
- Wash-out
Check diagnosis and age
Some historical kits required mixing
Do not transfer another product's timing
Check control and tolerability
Scalp oil is a distinct treatment plan
The reviewed fluocinolone acetonide 0.01% scalp oil is labeled for adult scalp psoriasis. Shake before use, thoroughly dampen the hair and scalp, apply a thin film to the scalp, massage and use the supplied shower cap. Leave for at least four hours or overnight, then shampoo and rinse thoroughly. Use daily as needed under the plan, stop when controlled and contact the clinician for no improvement at two weeks.
Do not transfer body-oil eligibility
The scalp label does not establish pediatric scalp-psoriasis use. Pediatric body-oil data do not confer that indication. Avoid intertriginous and diaper areas; facial use requires clinician direction. The prescribed cap is a product-specific application method, not permission to cover any other steroid preparation.
Clobetasol shampoo starts on a dry scalp
The reviewed clobetasol propionate 0.05% shampoo treats moderate to severe scalp psoriasis in adults at least 18 years old. Apply a thin film to affected dry scalp once daily; wait 15 minutes, then add water, lather and rinse thoroughly. Stop when controlled; limit use to four consecutive weeks and 50 mL/week. Reassess no improvement at four weeks. Do not copy the fluocinolone oil cap method: covering requires explicit clinician direction. Avoid face, groin, axillae, eyes and lips.
Clobetasol solution has a volume ceiling
The reviewed clobetasol 0.05% solution treats moderate to severe corticosteroid-responsive scalp dermatoses. Apply twice daily, limited to two consecutive weeks and 50 mL/week. Use below age 12 is not recommended. Primary scalp infections and ingredient hypersensitivity are contraindications. Do not cover with an occlusive dressing; avoid eye contact and open flame. Shampoo contact times do not apply.
Dispense clobetasol foam without melting it
The reviewed ordinary clobetasol 0.05% foam treats moderate to severe scalp plaque psoriasis and mild to moderate nonscalp plaque psoriasis from age 12, excluding face and folds. Apply twice daily for at most two weeks; stop when controlled and reassess nonresponse. Do not exceed 50 g or 21 capfuls weekly. Invert the can; dispense into its cap or onto affected skin, avoiding a warm palm unless treating the hands. Part hair to reach skin. Avoid flame and smoking during and immediately after use; occlusion requires clinician direction. These directions should not be transferred to an emulsion foam.
Read the historical shampoo as a preparation lesson
The reviewed Capex 0.01% fluocinolone kit is a historical seborrheic-dermatitis shampoo example; its DailyMed record gives an August 2023 marketing-end date. It was supplied with a capsule whose contents the pharmacist mixed into the shampoo before dispensing. The capsule was a preparation component, not an oral dose.
Contact time and disposal belong to the formulation
For that Capex kit, shake before use; the label specified no more than approximately one ounce once daily, worked into a lather for about five minutes before rinsing the hair and scalp thoroughly. Discard after two months. Pediatric safety and effectiveness were not established. Do not substitute these wash-out instructions for an oil, solution or foam.
Review response and tolerability
Confirm that the medicine reaches the scalp rather than coating only the hair. Avoid eyes, review irritation or persistent infection, and follow product-specific allergy precautions. Technique can explain nonresponse; increasing potency without checking delivery can increase harm.
Quick check
Checking for saved practice…
Lesson
Treat Medicated Tape as a Drug Delivery System
Tape dosing uses area, not fingertip units.
- Flurandrenolide
- Area
- Occlusion
- Replacement
A worked example
Length multiplied by width
Area multiplied by labeled loading
Do not equate content with absorption
Read the unit
Cordran tape contains flurandrenolide 4 mcg/cm², not 0.05% cream. It provides occlusion and suits localized dry, scaly responsive lesions; avoid weeping lesions and folds.
Teach handling
Cut rather than tear. Apply to clean, dry skin. Normally replace after 12 hours, then clean and allow one hour of drying; a prescribed 24-hour interval requires tolerability and adhesion.
Recognize a stop signal
Remove for irritation or infection and contact the prescriber. Keep the roll dry in its original tightly closed vial.
Separate content from absorption
A 2 cm by 3 cm piece contains 24 mcg: 6 cm² multiplied by 4 mcg/cm². That is drug in the tape, not a measured systemic dose.
Quick check
Checking for saved practice…
Lesson
Match Potency to Anatomy and Diagnostic Certainty
Eyelids, face, folds, groin, and genitals absorb more and develop atrophy more readily. Palms, soles, and lichenified plaques resist penetration. Hair and infection add another axis.
- Thin skin
- Thick skin
- Folds
- Hair
- Infection
Use a larger safety margin
Delivery can be difficult
Solution, foam, oil, or shampoo may improve reach
Confirm before suppressing inflammation
Protect thin and critical skin
Use a larger safety margin around eyelids, face, intertriginous folds, groin, and genitals. Ocular proximity and functional consequence often justify clinician review or a nonsteroid alternative.
Reach thick resistant skin
Palms, soles, and lichenified plaques can require a stronger formulation or different vehicle, but the plan still defines area, duration, and exit strategy.
Do not suppress an uncertain diagnosis
Annular scale, active borders, pustules, crust, pain, vesicles, burrows, dermatomal distribution, or treatment failure can signal infection or another mimic.
Prevent tinea incognito
Corticosteroids can reduce redness while a dermatophyte infection expands with altered morphology. Temporary cosmetic improvement is not proof of correct treatment.
Quick check
Checking for saved practice…
Lesson
Convert Apply Thinly Into a Reproducible Quantity
The fingertip unit translates a semisolid column into treated area and course quantity. It prevents both vague underdosing and uncontrolled excess.
- Standard nozzle
- One-half gram
- Two percent body area
- Course quantity
- Adherence
Assumes a 5 mm nozzle
An approximation, not a universal package constant
Two flat handprints, fingers included
Prescribe enough without uncontrolled excess
Define one unit
One adult fingertip unit is the amount expressed from the distal crease to the tip of the index finger through a 5 mm diameter nozzle.
Use the coverage estimate
One adult fingertip unit is approximately 0.5 g and covers roughly two adult handprints with fingers together. A handprint means one flat hand surface including the fingers, not both sides of the hand. About 2% adult body surface area is a teaching estimate, not an exact measured area for every person.
Distinguish a hand from a handprint
Covering the palm and back of one hand uses approximately the same amount as covering two separate handprints elsewhere. Specify which surface is being counted so that a patient does not halve the intended dose. The original 30-adult study found substantial variation in coverage, supporting demonstration rather than false precision.
Calculate the full course
Multiply units per application by applications per day and treatment days. Multiply by about one-half gram per unit when a gram estimate is required.
Teach the approximation
Nozzle diameter, formulation, hand, waste, and technique introduce variation. Demonstration and follow-up are more useful than pretending the estimate is exact.
Quick check
Checking for saved practice…
Lesson
Build the Exit Into the Starting Plan
Application frequency and duration follow the exact product, disease, site, response, and maintenance strategy. Once- or twice-daily use is common, but there is no universal schedule based only on potency.
- Frequency
- Control target
- Step-down
- Maintenance
- Treatment failure
Do not substitute more frequent use for reassessment
Stop or step down when the goal is reached
Not every disease needs continuous daily steroid
Recheck the diagnosis before increasing exposure
Follow product and disease directions
Do not convert the broad idea that some potent products work once daily into a universal rule. Read the label and the disease-specific treatment plan.
Reconcile AD guidance with the prescription
For uncontrolled atopic dermatitis treated with US class 1-5 corticosteroids or tacrolimus, the AAAAI/ACAAI guideline conditionally favors once-daily over twice-daily application, with moderate-certainty evidence. Twice daily may suit a more severe flare or patient preference. This disease-specific recommendation can inform a clinician-directed regimen differing from product labeling; clarify and document the intended plan rather than independently changing directions.
Reserve wet wraps for a defined rescue plan
For localized AD unresponsive to class 2-5 steroids or tacrolimus, the same guideline conditionally suggests a limited trial of class 3-7 steroid under wet wraps, based on very-low-certainty evidence. An example is once daily for 4-7 days, one hour to overnight. Teach technique, limit treated area, avoid constrictive wraps and monitor maceration or folliculitis. Reconcile the chosen product and covering with the clinician; this does not authorize unsupervised whole-body or super-high-potency occlusion.
Apply OTC stopping rules
The reviewed Trifecta hydrocortisone 1% cream permits up to 3-4 applications daily for labeled minor rashes in patients at least 2 years old. Stop and seek advice for worsening, persistence beyond seven days, or recurrence within a few days. Do not add another hydrocortisone product without medical advice. This label-specific ceiling is not a requirement to apply four times daily.
Apply to the intended field
Use the prescribed quantity on active disease or a specifically designated maintenance site. Wash hands afterward unless the hands are being treated.
Stop or step down when controlled
Continuing the initial potency indefinitely increases exposure without proving additional benefit. Move to barrier care, lower intensity, or prescribed intermittent maintenance.
Use a specific plan for recurrent atopic dermatitis
After remission, the AAAAI/ACAAI guideline supports proactive treatment of frequently recurring sites with a topical calcineurin inhibitor or a mid-potency steroid. A studied regimen is once daily on two consecutive days each week. This is a prescribed maintenance strategy, not permission for indefinite daily potent treatment.
Investigate failure before escalation
Check diagnosis, quantity, frequency, vehicle, adherence, contact allergy, infection, trigger persistence, package confusion, and access before increasing potency.
Quick check
Checking for saved practice…
Lesson
Recognize the Skin Pattern of Excess Exposure
Local toxicity includes atrophy, striae, telangiectasia, purpura, pigment change, acneiform eruption, rosacea, perioral dermatitis, infection masking, delayed healing, and contact allergy.
- Atrophy
- Striae
- Telangiectasia
- Infection masking
- Contact allergy
Thin skin is more vulnerable
Steroid suppression can reshape disease
Tinea incognito is a diagnostic warning
Follow the tissue trajectory
Inspect structure
Compare treated and untreated skin for thinning, transparency, striae, visible vessels, bruising, tearing, and loss of elasticity.
Recognize treatment-induced eruptions
Facial papules, pustules, rosacea-like change, perioral dermatitis, and acneiform lesions can be caused or perpetuated by corticosteroids.
Find concealed infection
Fungal borders can flatten, bacterial infection can spread, and viral lesions can worsen when inflammatory signals are suppressed.
Respond to visual symptoms
New blurred vision or other visual symptoms during topical corticosteroid use warrant clinical assessment and possible ophthalmology referral. Cataracts and glaucoma are labeled risks; skin application does not exclude ocular harm.
Consider product allergy and repair
Worsening, burning, delayed closure, or a new geometric border can reflect allergy to the active drug or vehicle, irritant exposure, or impaired healing.
Quick check
Checking for saved practice…
Lesson
Stack Every Factor That Raises Systemic Exposure
Topical therapy can suppress the HPA axis. Risk accumulates with potency, grams, area, duration, occlusion, barrier disruption, multiple steroid products, childhood, and impaired clearance.
- HPA axis
- Cushing features
- Hyperglycemia
- Occlusion
- Cumulative exposure
Percutaneous absorption increases
Track product-specific quantity limits
Hydration increases penetration
Withdrawal can expose adrenal insufficiency
Map the risk stack
Potency, area, duration, occlusion, and a disrupted barrier can raise percutaneous exposure. Multiple corticosteroid products add to the burden. Liver failure is a labeled risk factor for HPA suppression; impaired systemic handling should not be described as increased passage through the skin.
Recognize endocrine effects
Reversible HPA-axis suppression, Cushing features, hyperglycemia, glucosuria, and impaired growth can occur. Withdrawal after substantial exposure can reveal glucocorticoid insufficiency.
Use label limits precisely
The reviewed clobetasol emollient cream has a 50 g/week ceiling, but suppression has occurred at doses as low as 2 g/day. Staying below the weekly maximum does not guarantee endocrine safety. The label prohibits occlusive dressings and use on the face, groin, or axillae; avoid atrophic treatment sites.
Respond to documented suppression
Clinician-directed management may reduce frequency, substitute a less potent steroid, or gradually withdraw treatment. Symptoms of adrenal insufficiency may require systemic replacement. Do not abruptly discontinue substantial exposure without assessing the clinical situation.
Monitor proportionately
High-risk patients may require clinician-directed cortisol assessment or ACTH stimulation testing. Low-risk short courses do not need indiscriminate laboratory screening.
Quick check
Checking for saved practice…
Lesson
Adjust for Surface Area, Reserve, and Contact
Children have more skin area relative to body mass. Older adults may have fragile atrophic skin. Pregnancy and lactation require product-specific exposure and infant-contact planning.
- Children
- Diaper occlusion
- Older adults
- Pregnancy
- Lactation
Systemic exposure can rise
Use a deliberate site and duration plan
Use current product evidence, not retired letters
Follow product-specific nipple restrictions
Protect children from disproportionate exposure
Children can absorb a larger dose relative to body mass. Verify age labeling, treated percent body area, duration, caregiver quantity, growth, and unintentional diaper occlusion.
Separate pediatric prescribing from OTC self-care
For the reviewed hydrocortisone 1% cream, children under 2 need medical advice before use. Diaper rash requires clinician review; external anal itching in children under 12 also requires advice. A lower concentration alone does not establish infant self-care eligibility.
Protect fragile older skin
Baseline atrophy, purpura, anticoagulants, falls, wound risk, and caregiver application can magnify structural complications.
Replace pregnancy letters with exposure reasoning
Review the exact product, potency, area, duration, trimester, disease burden, alternatives, and current pregnancy evidence. Retired letter categories do not answer the question.
Interpret pregnancy evidence by outcome and design
Older observational findings raised concern about fetal growth with potent products and high cumulative exposure. A 2021 Danish matched cohort included 60,497 exposed pregnancies and found no increased risk of small-for-gestational-age birth or low birth weight overall. This is reassuring evidence for those outcomes, not proof that every product, exposure or pregnancy outcome is risk-free. Filled prescriptions do not establish actual use, and residual confounding remains possible.
Do not turn a study subgroup into a dosing threshold
A 2013 exploratory analysis reported a low-birth-weight association above 300 g of potent or very potent products during pregnancy; newer data did not confirm a clear increase. These observational cutoffs are not universal safe-dose limits. Choose effective treatment with the least necessary exposure, follow the exact product label, and review extensive or prolonged potent treatment with the treating clinician.
Prevent infant contact during lactation
Use product-specific lactation guidance. Avoid infant skin or oral contact with treated areas. The reviewed augmented betamethasone cream label advises against direct nipple or areola application; timing it after a feed does not override that restriction.
Quick check
Checking for saved practice…
Lesson
Measure Control and Total Exposure Together
Monitoring connects disease severity, treated area, grams, duration, site toxicity, adherence, infection, and quality of life. Barrier care and indicated nonsteroid agents can reduce recurrent steroid burden.
- Treatment target
- Exposure ledger
- Barrier care
- Steroid sparing
- Follow-up
Know what success means
Reconcile every product
Foundational care lowers treatment burden
Choose by indication, age, site, and safety
Define meaningful response
Track lesion area, thickness, scale, itch, sleep, pain, function, flare frequency, and patient goals rather than color alone.
Keep an exposure ledger
Record product, potency, grams, site, percent body area, frequency, days, occlusion, refills, and all inhaled, nasal, oral, injected, and combination steroids.
Build foundational care
Moisturizers, gentle cleansing, trigger control, infection management, and adherence support can lower anti-inflammatory demand in barrier diseases.
Use steroid-sparing therapy by indication
Topical calcineurin inhibitors, PDE4 inhibitors, JAK inhibitors, aryl hydrocarbon receptor agonists, phototherapy, and systemic options have disease-, age-, site-, and safety-specific roles. The AAD 2025 adult update adds support for tapinarof and roflumilast creams. Guidelines differ on topical JAK therapy: AAD supports it, while the 2023 AAAAI/ACAAI panel conditionally suggests against routine addition. Discuss benefit, uncertainty, safety and alternatives rather than calling all nonsteroid options equivalent.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 72 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- FDA Verdeso Product Record
- FDA Verdeso Historical Label
- AAAAI/ACAAI Topical Corticosteroid Supplement
- AAAAI/ACAAI Full Guideline and Potency Table
- DailyMed Mometasone Cream Label
- DailyMed Fluocinolone Solution Label
- DailyMed Flurandrenolide Ointment Label
- DailyMed Flurandrenolide Cream Label
- DailyMed Hydrocortisone Butyrate Cream, Ointment and Solution Label
- DailyMed Hydrocortisone Butyrate Lotion Label
- DailyMed Hydrocortisone 2.5 Percent Cream and Ointment Label
- DailyMed Fluocinonide 0.05 Percent Formulations Label
- DailyMed Fluocinonide Solution Label
- DailyMed Nonaugmented Betamethasone Dipropionate Label
- DailyMed Betamethasone Valerate Cream, Ointment and Lotion Label
- DailyMed Augmented Betamethasone Lotion Label
- DailyMed Clobetasol Cream, Gel and Ointment Label
- DailyMed Clobetasol Shampoo Label
- DailyMed Halobetasol Cream Label
- DailyMed Clobetasol Solution Label
- DailyMed Clobetasol Ordinary Foam Label
- DailyMed Clobetasol Emulsion Foam Label
- DailyMed Clobetasol Spray Label
- DailyMed Clobetasol Lotion Label
- DailyMed Halobetasol Ointment Label
- DailyMed Halobetasol Foam Label
- DailyMed Hydrocortisone 1 Percent Lotion Label
- DailyMed Hydrocortisone 1 Percent Ointment Label
- DailyMed Hydrocortisone 0.5 Percent Cream Label
- DailyMed Augmented Betamethasone Gel Label
- DailyMed Hydrocortisone 2.5 Percent Lotion Label
- DailyMed Triamcinolone Topical Aerosol
- DailyMed Fluocinolone Creams (ANI)
- DailyMed Fluocinolone Ointment and Cream (Cosette)
- DailyMed Flurandrenolide Lotion
- Andersson et al.: Pregnancy Cohort (2021)
- Chi et al.: Pregnancy Cohort (2013)
- DailyMed Fluocinolone Scalp Oil
- DailyMed Historical Capex Kit Label
- FDA Pandel Historical Label (2017)
- FDA Dermatop Cream Historical Label (2010)
- FDA Pandel Product Record
- FDA Prednicarbate Product Records
- Triamcinolone Acetonide Receptor Structure Study
- Triamcinolone Acetonide Receptor Activation Study
- DailyMed Fluticasone Cream
- DailyMed Fluticasone Lotion
- DailyMed Fluocinolone Body Oil
- DailyMed Alclometasone Cream (2025 SPL)
- DailyMed Alclometasone Ointment and Cream Label
- DailyMed Desonide Gel Label
- DailyMed Desonide Cream and Lotion Label
- DailyMed Hydrocortisone Butyrate Lipid Cream Label
- DailyMed Halobetasol 0.05% Lotion
- DailyMed Diflorasone Cream
- DailyMed Diflorasone Ointment
- DailyMed Desoximetasone Creams and Gel
- DailyMed Halcinonide Cream
- DailyMed Betamethasone Valerate Foam
- DailyMed Augmented Betamethasone Cream
- DailyMed Augmented Betamethasone Ointment
- DailyMed Fluocinonide 0.1% Cream
- DailyMed Mometasone 0.1% Ointment
- AAD Current Atopic Dermatitis Guidelines and Updates
- DailyMed Cordran Tape Label
- AAD Adult Atopic Dermatitis Topical Therapy Guideline
- AAAAI and ACAAI 2023 Atopic Dermatitis Guideline
- DailyMed Hydrocortisone 1 Percent Label
- DailyMed Clobetasol Emollient Cream Label
- DailyMed Triamcinolone Cream Label
- DailyMed Fluticasone Ointment Label
- Topical Corticosteroid Choice and Application Review
- British Association of Dermatologists: Topical Corticosteroids (April 2026)
- Long, Finlay and Averill: Rule of Hand
- Fingertip Unit Evidence